# Evaluating the Efficacy and Safety of Retatrutide in Obesity Management

Canonical source: https://retacompare.com/research/evaluating-the-efficacy-and-safety-of-retatrutide-in-obesity-management

Clinical Trials · 2025-04-18


    Retatrutide is being evaluated for its efficacy and safety in individuals with obesity or overweight. This ongoing clinical trial aims to provide insights into the potential benefits of retatrutide, particularly in subsets of participants with knee osteoarthritis and obstructive sleep apnea. The study is designed to last approximately 89 weeks and includes multiple visits for thorough assessment.


What this source covers

This study, registered under ClinicalTrials.gov (NCT05929066), focuses on the evaluation of retatrutide (LY3437943) in participants who are classified as having obesity or overweight. It includes specific subsets of participants suffering from knee osteoarthritis and obstructive sleep apnea. The trial is structured to last about 89 weeks, incorporating up to 24 visits, with an optional addendum allowing about 500 participants to continue treatment for an additional 24 weeks.


Why it matters for Retatrutide research

The findings from this study are significant as they will contribute to the understanding of retatrutide's role in weight management and its safety profile in individuals with comorbid conditions. Given the rising prevalence of obesity and its associated health risks, including knee osteoarthritis and obstructive sleep apnea, this research could inform future treatment protocols and guidelines. The trial's focus on diverse participant subsets enhances its relevance in addressing multifaceted health issues related to obesity.


Key findings or claims

The study evaluates the safety and efficacy of retatrutide in participants with obesity or overweight.

It includes subsets of participants with knee osteoarthritis and obstructive sleep apnea.

The trial duration is approximately 89 weeks with up to 24 visits.

An optional addendum allows for an additional 24 weeks of treatment for about 500 participants.


Context and prior work

Retatrutide is part of a broader class of medications that target the GLP-1, GIP, and glucagon pathways, which have shown promise in weight management and metabolic health. Prior research has indicated that these pathways play critical roles in appetite regulation and energy expenditure. Understanding how retatrutide interacts with these mechanisms could provide insights into its potential effectiveness compared to other weight loss treatments. This study adds to the existing body of literature by focusing on specific populations that may benefit from this therapeutic approach.


Practical takeaways for researchers

Researchers should consider the implications of retatrutide's efficacy in diverse populations, particularly those with additional health complications such as knee osteoarthritis and obstructive sleep apnea. The study's design, including the extended treatment phase for a subset of participants, may offer valuable data on long-term outcomes and safety. Additionally, findings from this trial could influence future research directions and clinical practices regarding obesity management.


FAQ

What is retatrutide?

Retatrutide (LY3437943) is a medication being studied for its effects on weight management in individuals with obesity or overweight.


How long will the study last?

The study is expected to last approximately 89 weeks, with up to 24 visits for participants.


Who can participate in this study?

The study is open to participants who are classified as having obesity or overweight, including those with knee osteoarthritis or obstructive sleep apnea.


Source: ClinicalTrials.gov · NCT05929066 · published 2025-04-18.

## Sources

- ClinicalTrials.gov · NCT05929066: https://clinicaltrials.gov/study/NCT05929066